TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20819525

Group type: EXPERIMENTAL
Intervention: Somatostatin administration (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No somatostatin (group A)
Number of subjects: 40
Study: 17393238

Group type: EXPERIMENTAL
Intervention: Atopic asthma group
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Groups divided by asthma severity
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Groups divided according to bronchial hyperresponsiveness
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: EDN and PC(20) correlation
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: ECP and PC(20) correlation
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: EDN and ECP correlation
Number of subjects: 151
Study: 15763644

Group type: EXPERIMENTAL
Intervention: octreotide pamoate and tamoxifen
Number of subjects: 150

Group type: COMPARATOR
Intervention: tamoxifen monotherapy
Number of subjects: 150
Study: 12086367

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Combination montelukast 10 mg and loratadine 10 mg
Number of subjects: 907

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Montelukast/loratadine vs Loratadine alone
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Montelukast/loratadine vs Placebo
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Montelukast/loratadine vs each therapy alone
Number of subjects: 907
Study: 9793700

Group type: EXPERIMENTAL
Intervention: s.c. naratriptan 1 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: s.c. naratriptan 5 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: s.c. naratriptan 10 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7629756

Group type: EXPERIMENTAL
Intervention: 150 micrograms Atrial natriuretic hormone (ANH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 IU arginine vasopressin (AVP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2117784

Group type: EXPERIMENTAL
Intervention: Group 1 (PaCO2 32-48 mm Hg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Group 2 (PaCO2 49-72 mm Hg)
Number of subjects: 25
Study: 351073

Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg on two consecutive days each week for six months)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (identical in appearance to levamisole)
Number of subjects: 99
Study: 31130273

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) with ropivacaine 0.5%, 20 ml
Number of subjects: 104

Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA) with ropivacaine 0.5%, 20 ml
Number of subjects: 104
Study: 28708930

Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Interval Training (HIIT)
Number of subjects: 63
Study: 24828126

Group type: EXPERIMENTAL
Intervention: Virtual Hope Box (VHB) smartphone app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional hope box integrated into VA behavioral health treatment
Number of subjects: 0
Study: 22899402

Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional pharmacologic treatment
Number of subjects: 155
Study: 21106046

Group type: EXPERIMENTAL
Intervention: Brimonidine twice daily (BID)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Brimonidine three times daily (TID)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Brimonidine TID
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Brimonidine BID
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Brimonidine BID and TID
Number of subjects: 37

Group type: COMPARATOR
Intervention: Open adherence monitoring
Number of subjects: 37
Study: 19765430

Group type: EXPERIMENTAL
Intervention: Basiliximab (2 doses)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Daclizumab (5 doses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (conventional therapies)
Number of subjects: 43
Study: 16751166

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intra-articular hylan G-F 20
Number of subjects: 60
Study: 14631226

Group type: EXPERIMENTAL
Intervention: Double bypass (hepaticojejunostomy and retrocolic gastrojejunostomy)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Single bypass (hepaticojejunostomy)
Number of subjects: 70
Study: 11063767

Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg in 50 mL saline, warmed to 37 degrees C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (2 mL distilled water in 50 mL saline)
Number of subjects: 30
Study: 9093709

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (5-fluorouracil and levamisole)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant chemotherapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 95
Study: 8096373

Group type: EXPERIMENTAL
Intervention: Zidovudine (two daily doses)
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study: 3532335

Group type: EXPERIMENTAL
Intervention: Low-dose (1 MU/m2) subcutaneous (SC) treatment 5 days per week, every other week, for eight weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose (50 MU/m2) intravenous (IV) treatment 5 days per week, every other week, for eight weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose (30 MU/m2) intravenous (IV) treatment three times per week for eight weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined use of alpha interferon and chemotherapeutic agents (VP-16 and vinblastine)
Number of subjects: 60
Study: 31206652

Group type: EXPERIMENTAL
Intervention: Early UST (after uterine closure; n=24)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Delayed UST (after skin closure; n=21)
Number of subjects: 45
Study: 29295269

Group type: EXPERIMENTAL
Intervention: User-centered design alerts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional alerts
Number of subjects: 0
Study: 25817062

Group type: EXPERIMENTAL
Intervention: Balloon inflation
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Cough trick
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control
Number of subjects: 132
Study: 23020840

Group type: EXPERIMENTAL
Intervention: Aggressive continuous passive motion for more than six hours per day
Number of subjects: 107

Group type: COMPARATOR
Intervention: Basic rehabilitation protocols (Control group)
Number of subjects: 107
Study: 21677649

Group type: EXPERIMENTAL
Intervention: Cue-elicited responses to alcohol taste cues
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: AUD severity
Number of subjects: 326
Study: 19059736

Group type: EXPERIMENTAL
Intervention: Classroom‐Centered (CC) intervention
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Depressed mood
Number of subjects: 563

Group type: COMPARATOR
Intervention: Family‐School Partnership (FSP) intervention
Number of subjects: 563
Study: 16567604

Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 528
Study: 12723461

Group type: EXPERIMENTAL
Intervention: RWJ 67657 (10 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RWJ 67657 (20 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RWJ 67657 (0.25-30 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11730394

Group type: EXPERIMENTAL
Intervention: Unopposed micronized 17beta‐estradiol (1 mg/d)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Unopposed micronized 17beta‐estradiol (1 mg/d) among women who did not receive lipid‐lowering medication
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo among women who did not receive lipid‐lowering medication
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Unopposed micronized 17beta‐estradiol (1 mg/d) among women who took lipid‐lowering medication
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo among women who took lipid‐lowering medication
Number of subjects: 222
Study: 9213324

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 8 courses
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 4 to 6 courses followed by high-dose chemotherapy with autologous peripheral blood stem-cell transplantation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 4 to 6 courses with G-CSF (filgrastim) followed by high-dose chemotherapy with autologous peripheral blood stem-cell transplantation
Number of subjects: 28
Study: 7970504

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg/day
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 2455105

Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lisinopril, 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine and Lisinopril combination
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study: 29549005

Group type: EXPERIMENTAL
Intervention: Nitrate supplement group (beetroot juice)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo group (black currant juice)
Number of subjects: 25
Study: 28288974

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 20702

Group type: EXPERIMENTAL
Intervention: Enalapril plus folic acid
Number of subjects: 20702
Study: 25684765

Group type: EXPERIMENTAL
Intervention: 3 mg/kg infliximab (IFX) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 mg/kg or 10 mg/kg infliximab (IFX) therapy
Number of subjects: 0
Study: 23160180

Group type: EXPERIMENTAL
Intervention: Increasing eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) intake
Number of subjects: 310
Study: 22125980

Group type: EXPERIMENTAL
Intervention: Coronal Z-type lengthening of transverse carpal ligament
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional open approach surgery
Number of subjects: 68
Study: 19246785

Group type: EXPERIMENTAL
Intervention: Self-adhesive polyurethane foam dressing
Number of subjects: 36
Study: 16290043

Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Isotonic Saline
Number of subjects: 101
Study: 15518675

Group type: EXPERIMENTAL
Intervention: Exercise deprivation for 1 week
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline measures of HPA axis, immune, and autonomic function
Number of subjects: 18
Study: 11083571

Group type: EXPERIMENTAL
Intervention: UltraPulse CO2 laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dermabrasion
Number of subjects: 20
Study: 9122733

Group type: EXPERIMENTAL
Intervention: CVD regimen (cisplatin, vinblastine, and dacarbazine) followed by rIFN‐α and rIL‐2
Number of subjects: 62
Study: 8301881

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3301505

Group type: EXPERIMENTAL
Intervention: Diltiazem (300 mg/die)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nifedipine (50 mg/die)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Verapamil (400 mg/die)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29911074

Group type: EXPERIMENTAL
Intervention: 28-day miltefosine monotherapy
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: 11-day combination therapy of miltefosine and liposomal amphotericin B (L-AMB)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Combination therapy (L-AMB)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Neopterin concentration increase
Number of subjects: 497
Study: 27111642

Group type: EXPERIMENTAL
Intervention: V‐Spec™ Monitoring System (pulse spectroscopy)
Number of subjects: 19
Study: 25142196

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) combined with antidepressant medication (ADM)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Antidepressant medication (ADM) alone
Number of subjects: 452
Study: 23363666

Group type: EXPERIMENTAL
Intervention: Daily bathing in chlorhexidine gluconate (CHG) 2%
Number of subjects: 4947

Group type: COMPARATOR
Intervention: Standard bathing practices
Number of subjects: 4947
Study: 20092709

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenous drip, once every 12 hours)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg intravenous injection, once every 8 hours)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combination therapy (Erythromycin and Metoclopramide)
Number of subjects: 152
Study: 17932089

Group type: EXPERIMENTAL
Intervention: Full-CAT (Cognitive Adaptation Training focused on community adaptation including grooming, care of living quarters, leisure skills, social and role performance, and medication adherence)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Pharm-CAT (Cognitive Adaptation Training focused only on medication and appointment adherence)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 95
Study: 21703078

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) brands used for restorations (specific brands not detailed)
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Postrestoration meal of 'hard consistency'
Number of subjects: 804

Group type: COMPARATOR
Intervention: Glass ionomer cement brands
Number of subjects: 804
Study: 16220400

Group type: EXPERIMENTAL
Intervention: 22‐day fractionation schedule (2.5 Gy to 55 Gy, 4x/week, n = 65)
Number of subjects: 129

Group type: COMPARATOR
Intervention: 28-day conventional fractionation schedule (2.0 Gy to 55 Gy, 5x/week, n = 64)
Number of subjects: 129
Study: 11891037

Group type: EXPERIMENTAL
Intervention: Talc pleurodesis with patient rotation for 1 hour
Number of subjects: 20

Group type: COMPARATOR
Intervention: Talc pleurodesis with patients remaining in stable supine position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Talc dispersion after rotation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Talc dispersion without rotation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Scintigraphic imaging after 1 hour
Number of subjects: 20
Study: 11477828

Group type: EXPERIMENTAL
Intervention: TTS‐ST93‐1 plaster
Number of subjects: 163

Group type: COMPARATOR
Intervention: TTS‐Scopolamine plaster
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo (lactose plaster)
Number of subjects: 163
Study: 7648374

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2670634

Group type: EXPERIMENTAL
Intervention: 200 mg/day nimesulide
Number of subjects: 40

Group type: COMPARATOR
Intervention: 500 mg/day naproxen
Number of subjects: 40
Study: 13003

Group type: EXPERIMENTAL
Intervention: Flexible plastic cannula
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Nonflexible plastic cannula
Number of subjects: 1100
Study: 11319723

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol intake of up to approximately 800 mg/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Insulin-resistant women
Number of subjects: 65

Group type: COMPARATOR
Intervention: Insulin-sensitive women
Number of subjects: 65
Study: 31208472

Group type: EXPERIMENTAL
Intervention: iHIVARNA-01 (HIVACAT T-cell immunogen (HTI)-TriMix)
Number of subjects: 100

Group type: COMPARATOR
Intervention: TriMix
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water for injection (WFI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: iHIVARNA-01
Number of subjects: 100

Group type: COMPARATOR
Intervention: WFI
Number of subjects: 100
Study: 28914724

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic walking
Number of subjects: 159

Group type: COMPARATOR
Intervention: Nonaerobic stretching and toning
Number of subjects: 159
Study: 26999823

Group type: COMPARATOR
Intervention: Standard web-based intervention
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 69
Study: 25376417

Group type: EXPERIMENTAL
Intervention: Health promotion program
Number of subjects: 0
Study: 23359970

Group type: EXPERIMENTAL
Intervention: Fuzheng Fujia Mixture (FFM), 3 times daily for one month as 1 therapeutic course, in addition to Levothyroxine Sodium Tablet (LST) as routine treatment.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Levothyroxine Sodium Tablet (LST) as routine treatment.
Number of subjects: 60
Study: 19852964

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin
Number of subjects: 320

Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (genotype 1/4)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (genotype 1/4)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (genotype 2/3)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (genotype 2/3)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (without cirrhosis)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (without cirrhosis)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (HCV RNA >500,000 IU/mL)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (HCV RNA >500,000 IU/mL)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (baseline HCV RNA <or=500,000 IU/mL)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (baseline HCV RNA <or=500,000 IU/mL)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (cirrhosis)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (cirrhosis)
Number of subjects: 320
Study: 18066962

Group type: EXPERIMENTAL
Intervention: Thrombophilia screening protocol including hereditary thrombophilic disorders, antiphospholipid antibodies, and hyperhomocysteinemia.
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Hereditary thrombophilia
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 216
Study: 15906077

Group type: EXPERIMENTAL
Intervention: Hepburn heart and lung exerciser (HHALE) training for 6 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (ceased training after 6 weeks)
Number of subjects: 18
Study: 12581422

Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage‐colony stimulating factor alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic fibroblast growth factor alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage‐colony stimulating factor and basic fibroblast growth factor given in sequence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10583355

Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Intra-articular fentanyl
Number of subjects: 107
Study: 8708963

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) technique using expanded polytetrafluoroethylene (ePTFE) barriers
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional periodontal surgery
Number of subjects: 16

Group type: COMPARATOR
Intervention: Computer-assisted system
Number of subjects: 16
Study: 1931532

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (therapeutic dosage, serum levels of 10-20 micrograms/ml) for two months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for two months
Number of subjects: 24
Study: 7145250

Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clonidine 0.4 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30819457

Group type: EXPERIMENTAL
Intervention: 8-week STP-PreK
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4-week STP-PreK
Number of subjects: 45

Group type: COMPARATOR
Intervention: school year behavioral consultation (SC)
Number of subjects: 45
Study: 29500534

Group type: EXPERIMENTAL
Intervention: Day-case surgery (DCS) group
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional hospitalization (CH) group
Number of subjects: 124
Study: 26056021

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistive exercise only (RE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Long-term recovery (RVE vs control)
Number of subjects: 24
Study: 24495633

Group type: EXPERIMENTAL
Intervention: The COACH Program plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 22369708

Group type: EXPERIMENTAL
Intervention: Pamphlet and reminder (A)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Pamphlet only (B)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 242
Study: 21126295

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (all-in-one self-etch adhesive; 3M ESPE) after water cleansing
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (self-etch primer system; Kuraray America) after water cleansing
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Adper Easy Bond (all-in-one self-etch adhesive; 3M ESPE)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saliva contamination without cleansing
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saliva and cleansing with water
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saliva and cleansing with 2% chlorhexidine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saliva and cleansing with 5% sodium hypochlorite
Number of subjects: 75
Study: 18260945

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 70

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 70